Medina-Chávez JH, Colín-Luna JI, Mendoza-Martínez P, Santoyo-Gómez DL, Cruz-Aranda JE

Language: Spanish
References: 11
Page: 344-356
PDF size: 240.07 Kb.

ABSTRACT

The disease caused by SARS-CoV-2, COVID 19, has become a pandemic due to its rapid spread and transmissibility. It has a wide spectrum of manifestation, from a self-limited disease to fulminant pneumonia, among the most vulnerable patients are the elderly and those with chronic diseases, such as high blood pressure and diabetes mellitus. The prevalence of diabetes mellitus in Mexico is 10.3%, a considerable number if we take into account that these are people who know they have the disease. Due to the above, there is concern about the management of hyperglycemia in patients with diabetes mellitus and COVID-19 infection, given that observational and randomized controlled studies indicate that the improvement in glycemic control in different hospital settings has improved the results in terms of decrease in the incidence of complications and mortality. A review and consensus regarding the management in the different clinical scenarios for patients with diabetes mellitus and hyperglycemia as a consequence of metabolic stress or side effects of some drugs was performed in order to have evidence and a quick reference of management for these patients who may be affected by COVID-19 and provide more comprehensive management.

REFERENCES

1. Wang W, Zhao Z, Xu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Research Clinical Practice 2020. doi: https://doi.org/10.1016/j. diabres.2020.108118.

2. INEGI-INSP (2019). Encuesta Nacional de Salud y Nutrición 2018 Ensanut-Presentación de Resultados. Disponible en: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/ informes/ensanut_2018_presentacion_resultados.pdf.

3. Lineamiento para la atención de pacientes por COVID-19. Disponible en: https://www.insp.mx/nuevo-coronavirus- 2019/documentos-materiales-interes.html.

4. Umpierrez G, Hellman R, Korytkowski M, Kosiborod M, Maynard G, Montori V, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97(1):16-38. doi: 10.1210/jc.2011-2098.

5. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr 2020 Mar 10;14(3):211-212. doi: 10.1016/j.dsx.2020.03.002.

6. American Diabetes Association. 15. Diabetes care in the hospital: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S193-S202. https://doi. org/10.2337/dc20-S015.

7. Khazai NB, Hamdy O. Inpatient diabetes management in the twenty-first century. Endocrinol Metab Clin North Am 2016;45(4):875-894. doi: 10.1016/j.ecl.2016.06.013.

8. Perez A, et al. Hospital management of hyperglycemia. Med Clin (Barc) 2009;132:465-475. doi: 10.1016/j.medcli. 2009.02.001.

9. Joslin. Diabetes Center Medical Intensive Care Unit Protocol. 2015.

10. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131. doi: 10.2337/dc09-9029

11. Abraham MB, Jones TW, Naranjo D, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2018;19(Suppl. 27):178-192. https://doi.org/10.1111/pedi.12698.